1,2-Naphthoquinone Derivative for Leukemia Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) are limited by drug resistance and side effects, with existing anticancer drugs failing to achieve complete treatment and causing harm to normal cells, necessitating the development of novel therapies.
Innovation Solution
A pharmaceutical composition containing a 1,2-naphthoquinone derivative compound, which can be formulated into various dosage forms, is used to treat drug-resistant or refractory AML and ALL, offering an effective cell-killing effect without significant harm to normal cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional chemotherapy drugs are used to treat acute leukemia, then cancer cell killing activity is achieved, but drug resistance develops and normal cells are harmed
Solution Approach 1:
The patent modifies the chemical structure of naphthoquinone compounds by introducing specific substituents (e.g., at positions 3, 4, 5, 6, 7, or 8) to change the pharmacological parameters of the drug, thereby improving selectivity between cancer cells and normal cells while maintaining cytotoxic activity against leukemia cells
Solution Approach 2:
The patent utilizes the inherent cytotoxicity of naphthoquinone compounds against cancer cells and redirects this harmful effect toward selective cancer cell killing by structural modification, converting a non-selective toxin into a selective anticancer agent that spares normal cells
2Productivity
If existing anticancer drugs are administered, then some cancer cells are killed, but complete treatment is not achieved due to drug resistance
Solution Approach 1:
The patent divides the treatment approach by creating multiple structurally distinct naphthoquinone derivatives (compounds 1-10 with different substitution patterns), allowing combination therapy or sequential treatment to overcome resistance mechanisms that affect individual drugs
Solution Approach 2:
The patent combines naphthoquinone core structure with various functional groups and substituents to create composite molecular structures with enhanced and diversified anticancer activities, improving the overall treatment efficacy against resistant leukemia cells
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention relates to a pharmaceutical composition for preventing or treating solid cancer and blood cancers such as acute leukemia and chronic leukemia, comprising a derivative compound of 1,2-naphthoquinone or a pharmaceutically acceptable salt thereof as an effective component. The derivative compound of 1,2-naphthoquinone is highly effective in killing cancer cells of various solid cancers, acute leukemia, and chronic leukemia, and thus can be beneficially used as a pharmaceutical composition for preventing or treating cancers, especially solid cancers, acute leukemia, and chronic leukemia.